Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
Date
2022-12-01Author
Loveday, C
Garrett, A
Law, P
Hanks, S
Poyastro-Pearson, E
Adlard, JW
Barwell, J
Berg, J
Brady, AF
Brewer, C
Chapman, C
Cook, J
Davidson, R
Donaldson, A
Douglas, F
Greenhalgh, L
Henderson, A
Izatt, L
Kumar, A
Lalloo, F
Miedzybrodzka, Z
Morrison, PJ
Paterson, J
Porteous, M
Rogers, MT
Walker, L
Breast and Ovarian Cancer Susceptibility Collaboration,
Eccles, D
Evans, DG
Snape, K
Hanson, H
Houlston, RS
Turnbull, C
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Breast cancer has a significant heritable basis, of which ∼60% remains unexplained. Testing for BRCA1/BRCA2 offers useful discrimination of breast cancer risk within families, and identification of additional breast cancer susceptibility genes could offer clinical utility. PATIENTS AND METHODS: We included 2135 invasive breast cancer cases recruited via the Breast and Ovarian Cancer Susceptibility study, a retrospective UK study of familial breast cancer. ELIGIBILITY CRITERIA: female, BRCA-negative, white European ethnicity, and one of: (i) breast cancer family history, (ii) bilateral disease, (iii) young age of onset (<30 years), and (iv) concomitant ovarian cancer. We undertook exome sequencing of cases and carried out gene-level burden testing of rare damaging variants against those from 51 377 ethnicity-matched population controls from gnomAD. RESULTS: 159/2135 (7.4%) cases had a qualifying variant in an established breast cancer susceptibility gene, with minimal evidence of signal in other cancer susceptibility genes. Known breast cancer susceptibility genes PALB2, CHEK2, and ATM were the only genes to retain statistical significance after correcting for multiple testing. Due to the enrichment of hereditary cases in the series, we had good power (>80%) to detect a gene of BRCA1-like risk [odds ratio (OR) = 10.6] down to a population minor allele frequency of 4.6 × 10-5 (1 in 10 799, less than one-tenth that of BRCA1)and of PALB2-like risk (OR = 5.0) down to a population minor allele frequency of 2.8 × 10-4 (1 in 1779, less than half that of PALB2). Power was lower for identification of novel moderate penetrance genes (OR = 2-3) like CHEK2 and ATM. CONCLUSIONS: This is the largest case-control whole-exome analysis of enriched breast cancer published to date. Whilst additional breast cancer susceptibility genes likely exist, those of high penetrance are likely to be of very low mutational frequency. Contention exists regarding the clinical utility of such genes.
Collections
Subject
breast cancer
cancer susceptibility genes
genetic susceptibility
rare-variant burden testing
whole-exome sequencing
Female
Humans
Adult
Germ-Line Mutation
Breast Neoplasms
Triple Negative Breast Neoplasms
Retrospective Studies
Genetic Predisposition to Disease
Ovarian Neoplasms
Research team
Cancer Genomics
Translational Genetics
Language
eng
Date accepted
2022-09-01
License start date
2022-12-01
Citation
Annals of Oncology, 2022, 33 (12), pp. 1318 - 1327
Publisher
ELSEVIER
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
LAUNCH OF THE BREAST SCREENING AFTER RADIOTHERAPY DATASET - AN ENGLAND WIDE INITIATIVE TO IMPROVE SCREENING FOR BREAST CANCER IN 9,000 WOMEN AT HIGH RISK FOLLOWING RADIOTHERAPY TO BREAST TISSUE UNDER AGE 36
Radford, J; Howell, S; Vaughan, K; Goode, V; Worthington, D; et al. (FERRATA STORTI FOUNDATION, 2016-10-01) -
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Haviland, JS; Hopwood, P; Mills, J; Sydenham, M; Bliss, JM; et al. (ELSEVIER SCIENCE LONDON, 2016-06-01)AIMS: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data ... -
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial
Coles, C; Griffin, C; Kirby, A; Titley, J; Agrawal, R; et al. (2017-05-15)